Table 1.

Patient and treatment characteristics

VariableValue
Subjects
N42
 age (years)56.8±15.5
 sex (male/female)25/17
 weight (kg)95.1±26.8
 AKI36/42
 24-hour urine output (ml)38 (157)
 CCF score (n=36)7.9±2.8
 survival (%)50.0
 center (CCF/UAB)19/23
Treatment
 CRRT mode (CVVHD/CVVHDF)19/23
 CRRT dose (ml/kg per hour)25.7 (15.8)
 CRRT machine (Prismaflex/NxStage)34/8
 piperacillin dose (2 g/3 g)19/23
 piperacillin dosing interval (6 h/8 h/12 h)23/16/3
 cumulative 24-hour piperacillin dose (g)8.6±1.5
  • Data are presented as mean ± SD or median (intraquartile range). CCF, Cleveland Clinic, Cleveland, Ohio; UAB, University of Alabama, Birmingham, Alabama; CRRT, continuous renal replacement therapy; CVVHD, continuous venovenous hemodialysis; CVVHDF, continuous venovenous hemodiafiltration.